September delivered several developments in renal cell carcinoma (RCC). Highlights included real-world findings on belzutifan (Welireg)–related adverse effects across tumor types, insights from the phase 1 STELLAR-002 trial (NCT05176483)…
RCC Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025
